Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

Literature DB >> 28819727

Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.

Abstract

Oral abiraterone acetate (Zytiga®) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC. In the pivotal global phase 3 trials, relative to placebo (+prednisone), abiraterone acetate (+prednisone) prolonged overall survival (OS) at data maturity (final analysis) and radiographic progression-free survival (rPFS) at all assessed timepoints. Given its efficacy in prolonging OS and its convenient once-daily oral regimen, in combination with prednisone, abiraterone acetate is an important first-line option for the treatment of mCRPC.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 28819727 DOI： 10.1007/s40265-017-0799-9

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

48 in total

1. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing.

Authors: Kouichi Inoue; Akira Shishido; Nicole Vaccaro; James Jiao; Hans Stieltjes; Apexa Bernard; Margaret Yu; Caly Chien
Journal: Cancer Chemother Pharmacol Date: 2014-10-25 Impact factor: 3.333

Review 2. Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials.

Authors:
Journal: Clin Adv Hematol Oncol Date: 2016-04

Review 3. Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors: Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal: Can Urol Assoc J Date: 2016-12-12 Impact factor: 1.862

4. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

Authors: Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland
Journal: Lancet Oncol Date: 2013-09-25 Impact factor: 41.316

5. Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.

Authors: Hung-Ming Lam; Ryan McMullin; Holly M Nguyen; Ilsa Coleman; Michael Gormley; Roman Gulati; Lisha G Brown; Sarah K Holt; Weimin Li; Deborah S Ricci; Karin Verstraeten; Shibu Thomas; Elahe A Mostaghel; Peter S Nelson; Robert L Vessella; Eva Corey
Journal: Clin Cancer Res Date: 2016-12-19 Impact factor: 12.531

6. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.

Authors: K N Chi; A Tolcher; P Lee; P J Rosen; C K Kollmannsberger; K P Papadopoulos; A Patnaik; A Molina; J Jiao; C Pankras; B Kaiser; A Bernard; N Tran; M Acharya
Journal: Cancer Chemother Pharmacol Date: 2012-10-12 Impact factor: 3.333

7. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.

Authors: Charles J Ryan; Arturo Molina; Jinhui Li; Thian Kheoh; Eric J Small; Christopher M Haqq; Russell P Grant; Johann S de Bono; Howard I Scher
Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544

Review 8. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.

Authors: Sheridan M Hoy
Journal: Drugs Date: 2013-12 Impact factor: 9.546

9. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Authors: K N Chi; T Kheoh; C J Ryan; A Molina; J Bellmunt; N J Vogelzang; D E Rathkopf; K Fizazi; P W Kantoff; J Li; A A Azad; B J Eigl; D Y C Heng; A M Joshua; J S de Bono; H I Scher
Journal: Ann Oncol Date: 2015-12-18 Impact factor: 32.976

10. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Authors: Johann S de Bono; Matthew R Smith; Fred Saad; Dana E Rathkopf; Peter F A Mulders; Eric J Small; Neal D Shore; Karim Fizazi; Peter De Porre; Thian Kheoh; Jinhui Li; Mary B Todd; Charles J Ryan; Thomas W Flaig
Journal: Eur Urol Date: 2016-07-09 Impact factor: 20.096

8 in total

Review 1. Enzalutamide: A Review in Castration-Resistant Prostate Cancer.

Authors: Lesley J Scott
Journal: Drugs Date: 2018-12 Impact factor: 9.546

Review 2. Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors: F Peter Guengerich; Francis K Yoshimoto
Journal: Chem Rev Date: 2018-06-22 Impact factor: 60.622

3. Conformational selection dominates binding of steroids to human cytochrome P450 17A1.

Authors: F Peter Guengerich; Clayton J Wilkey; Sarah M Glass; Michael J Reddish
Journal: J Biol Chem Date: 2019-05-09 Impact factor: 5.157

Review 4. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors: Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal: J Hematol Oncol Date: 2022-10-08 Impact factor: 23.168